Cargando…

Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt’s Lymphoma

Background Burkitt's lymphoma (BL) in the pediatric population has significant burden in developing countries. Infection-related complications during the induction chemotherapy phase pose a major challenge and contribute to high mortality rates due to a severely immunocompromised state. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibne Ali Jaffari, Syed Muhammad, Hashmi, Masooma, Hashmi, Abdul Wasey, Nisar, Samaha, Ashraf, Hafsa, Tariq, Ghufran, Farooq, Arslan, Awan, Javeria, Zaidi, Syed Muhammad Jawad, Kaneez, Mehwish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340133/
https://www.ncbi.nlm.nih.gov/pubmed/37456486
http://dx.doi.org/10.7759/cureus.40365
_version_ 1785072005686493184
author Ibne Ali Jaffari, Syed Muhammad
Hashmi, Masooma
Hashmi, Abdul Wasey
Nisar, Samaha
Ashraf, Hafsa
Tariq, Ghufran
Farooq, Arslan
Awan, Javeria
Zaidi, Syed Muhammad Jawad
Kaneez, Mehwish
author_facet Ibne Ali Jaffari, Syed Muhammad
Hashmi, Masooma
Hashmi, Abdul Wasey
Nisar, Samaha
Ashraf, Hafsa
Tariq, Ghufran
Farooq, Arslan
Awan, Javeria
Zaidi, Syed Muhammad Jawad
Kaneez, Mehwish
author_sort Ibne Ali Jaffari, Syed Muhammad
collection PubMed
description Background Burkitt's lymphoma (BL) in the pediatric population has significant burden in developing countries. Infection-related complications during the induction chemotherapy phase pose a major challenge and contribute to high mortality rates due to a severely immunocompromised state. However, there is scarce data on the etiologies and optimal management strategies for infection-related mortality in pediatric BL patients, especially in developing countries like Pakistan. Methods This is a cross-sectional study that included a total of 116 pediatric patients with intermediate-risk BL. All patients were treated based on the Children’s Cancer and Leukaemia Group (CCLG) 2020 guidelines. Data on patient demographics, presenting symptoms, diagnosis, infectious etiologies, and outcomes were collected. Infection-related complications and mortality were monitored during the induction chemotherapy period. The results of relevant culture reports were tabulated and data were analyzed. Results Among the 116 included patients, 61.1% were males with a mean age of 4.83 ± 2.12 years. Abdominal BL was the most common anatomical location. During the induction period, 66 patients (56.9%) had culture-proven infections, resulting in 33 deaths (28.4%). Fever was the predominant presenting symptom in all patients, followed by vomiting (57.6%), loose stools (42.4%), and cough (18.2%). Neutropenic colitis, sepsis, pneumonia, and meningitis were among the diagnosed infections. Hospital-acquired bacterial infections, including multi-drug resistant gram-negative and gram-positive organisms, were the main cause of mortality, with fungal infections and cytomegalovirus viremia also identified in a few patients. Conclusions This study highlights the urgent need for improved management strategies in pediatric BL patients in Pakistan to reduce infection-related complications and mortality rates, emphasizing the importance of context-specific approaches for infection prevention and management.
format Online
Article
Text
id pubmed-10340133
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-103401332023-07-14 Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt’s Lymphoma Ibne Ali Jaffari, Syed Muhammad Hashmi, Masooma Hashmi, Abdul Wasey Nisar, Samaha Ashraf, Hafsa Tariq, Ghufran Farooq, Arslan Awan, Javeria Zaidi, Syed Muhammad Jawad Kaneez, Mehwish Cureus Pediatrics Background Burkitt's lymphoma (BL) in the pediatric population has significant burden in developing countries. Infection-related complications during the induction chemotherapy phase pose a major challenge and contribute to high mortality rates due to a severely immunocompromised state. However, there is scarce data on the etiologies and optimal management strategies for infection-related mortality in pediatric BL patients, especially in developing countries like Pakistan. Methods This is a cross-sectional study that included a total of 116 pediatric patients with intermediate-risk BL. All patients were treated based on the Children’s Cancer and Leukaemia Group (CCLG) 2020 guidelines. Data on patient demographics, presenting symptoms, diagnosis, infectious etiologies, and outcomes were collected. Infection-related complications and mortality were monitored during the induction chemotherapy period. The results of relevant culture reports were tabulated and data were analyzed. Results Among the 116 included patients, 61.1% were males with a mean age of 4.83 ± 2.12 years. Abdominal BL was the most common anatomical location. During the induction period, 66 patients (56.9%) had culture-proven infections, resulting in 33 deaths (28.4%). Fever was the predominant presenting symptom in all patients, followed by vomiting (57.6%), loose stools (42.4%), and cough (18.2%). Neutropenic colitis, sepsis, pneumonia, and meningitis were among the diagnosed infections. Hospital-acquired bacterial infections, including multi-drug resistant gram-negative and gram-positive organisms, were the main cause of mortality, with fungal infections and cytomegalovirus viremia also identified in a few patients. Conclusions This study highlights the urgent need for improved management strategies in pediatric BL patients in Pakistan to reduce infection-related complications and mortality rates, emphasizing the importance of context-specific approaches for infection prevention and management. Cureus 2023-06-13 /pmc/articles/PMC10340133/ /pubmed/37456486 http://dx.doi.org/10.7759/cureus.40365 Text en Copyright © 2023, Ibne Ali Jaffari et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Pediatrics
Ibne Ali Jaffari, Syed Muhammad
Hashmi, Masooma
Hashmi, Abdul Wasey
Nisar, Samaha
Ashraf, Hafsa
Tariq, Ghufran
Farooq, Arslan
Awan, Javeria
Zaidi, Syed Muhammad Jawad
Kaneez, Mehwish
Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt’s Lymphoma
title Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt’s Lymphoma
title_full Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt’s Lymphoma
title_fullStr Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt’s Lymphoma
title_full_unstemmed Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt’s Lymphoma
title_short Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt’s Lymphoma
title_sort infection-associated mortality during induction chemotherapy in group b intermediate-risk pediatric burkitt’s lymphoma
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340133/
https://www.ncbi.nlm.nih.gov/pubmed/37456486
http://dx.doi.org/10.7759/cureus.40365
work_keys_str_mv AT ibnealijaffarisyedmuhammad infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma
AT hashmimasooma infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma
AT hashmiabdulwasey infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma
AT nisarsamaha infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma
AT ashrafhafsa infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma
AT tariqghufran infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma
AT farooqarslan infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma
AT awanjaveria infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma
AT zaidisyedmuhammadjawad infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma
AT kaneezmehwish infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma